Medtronic's latest regulatory wins further support its fast-growing arrhythmia-treating cardiac ablation business.

Despite having an implantable cardioverter-defibrillator, a 62-year-old woman suffered from ongoing atrial fibrillation and ...

The regulatory authorizations come as Medtronic looks to differentiate itself in the fast-growing pulsed field ablation ...

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug ...

As Boston Scientific, Medtronic, Abbott, and J&J battle for PFA market share, Pulse Biosciences could rewrite the competitive ...

The new regulatory approvals expand Medtronic’s mapping and tissue-proximity capabilities for cardiac ablation.

Cryoballoon (CB) ablation is as effective at reducing recurrences of atrial fibrillation (AF) and atrial tachycardia (AT) at 1-year, when compared to the current most widely used technique, ...

For patients with atrial fibrillation, catheter ablation reduces the risk of ischemic stroke at more than 30 days, mortality, and heart failure hospitalization, while surgical ablation only reduces ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tailored ablation guided by AI better prevented atrial ...

Cardiac arrhythmias are a leading cause of morbidity and mortality worldwide. Catheter ablation provides a minimally invasive means to target and eliminate arrhythmogenic substrates within the heart.

Compared with medical therapy, rhythm control with catheter ablation is associated with lower risk of ischemic stroke after 30 days, as well as less mortality and heart failure (HF) hospitalization, ...

Recent advances in ablation techniques have introduced new technologies ...